CC# 159518 A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer

-
Investigator: Pamela N. Munster, MD
Sponsor: MedImmune, Inc

Location(s): United States

Description

To evaluate MEDI9197 when administered by intratumoral injection to subjects with solid tumor cancers.